Kimyrsa is developed by Melinta Therapeutics, Inc..

What development phase is Kimyrsa in?

Kimyrsa is FDA-approved (marketed).

Last reviewed 2026-04-20 · How we verify

Kimyrsa

Melinta Therapeutics, Inc. · FDA-approved active Small molecule

At a glance

Generic name	Kimyrsa
Also known as	Oritavancin
Sponsor	Melinta Therapeutics, Inc.
Modality	Small molecule
Therapeutic area	Other
Phase	FDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Study to Evaluate the Safety of Intravenous Oritavancin for the Treatment of Children With Skin Infections (PHASE2)
Relative Exposure and Safety Study of Kimyrsa in ABSSSI Patients (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Kimyrsa CI brief — competitive landscape report
Kimyrsa updates RSS · CI watch RSS
Melinta Therapeutics, Inc. portfolio CI